Skip to Content Skip to Search

Results announcement for the first quarter 2012

- Sales growth of +2% CER - Further R&D delivery, operational leverage and continued returns to shareholders - Core EPS 27.3p (+7%), dividend up 6% to 17p

Issued: London UK

  • Sales growth of +2% CER
  • Further R&D delivery, operational leverage and continued returns to shareholders
  • Core EPS 27.3p (+7%), dividend up 6% to 17p

Full announcement and CFO video available in the Investors section of this website.

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

 

+44 (0) 20 8047 5502

 

(London)

 

Stephen Rea

 

+44 (0) 20 8047 5502

 

(London)

 

Sarah Spencer

 

+44 (0) 20 8047 5502

 

(London)

 

David Daley

 

+44 (0) 20 8047 5502

 

(London)

 

 

 

 

 

 

US Media enquiries:

Kevin Colgan

 

+1 919 483 2839

 

(North Carolina)

 

Melinda Stubbee

 

+1 919 483 2839

 

(North Carolina)

 

Sarah Alspach

 

+1 919 483 2839

 

(Washington, DC)

 

Jennifer Armstrong

 

+1 919 483 2839

 

(Philadelphia)

 

         

Analyst/Investor enquiries:

Sally Ferguson

 

+44 (0) 20 8047 5543

 

(London)

 

Tom Curry

 

+ 1 215 751 5419

 

(Philadelphia)

 

Gary Davies

 

+ 44 (0) 20 8047 5503

 

(London)

 

Jeff McLaughlin

 

+ 1 215 751 7002

 

(Philadelphia)

 

Ziba Shamsi

 

+ 44 (0) 20 8047 3289

 

(London)